Keryx Biopharmaceuticals (KERX)

8.04 +0.04  +0.50%  May 17, 8:00PM
Add to Watchlists Create an Alert

Keryx Biopharmaceuticals R&D Expense Quarterly:

4.753M for Dec. 31, 2012
View Full Chart

Keryx Biopharmaceuticals R&D Expense Quarterly Chart

    Keryx Biopharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 4.753M
    Sept. 30, 2012 3.768M
    June 30, 2012 3.799M
    March 31, 2012 7.122M
    Dec. 31, 2011 6.676M
    Sept. 30, 2011 8.62M
    June 30, 2011 6.50M
    March 31, 2011 4.618M
    Dec. 31, 2010 4.144M
    Sept. 30, 2010 3.901M
    June 30, 2010 3.563M
    March 31, 2010 2.554M
    Dec. 31, 2009 3.298M
    Sept. 30, 2009 1.915M
    June 30, 2009 1.817M
    March 31, 2009 1.575M
    Dec. 31, 2008 1.126M
    Sept. 30, 2008 2.542M
    June 30, 2008 4.493M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
       
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro
    Sept. 30, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    KERX R&D Expense Quarterly Benchmarks

    Companies
    Supernus Pharmaceuticals 5.15M
    Aegerion Pharmaceuticals 5.775M
    Sucampo Pharmaceuticals

    KERX R&D Expense Quarterly Rankings

    Overall 88th percentile
    852 of 7593
    Sector 62nd percentile
    242 of 650 in Healthcare
    Industry 46th percentile
    35 of 65 in Drug Manufacturers - Specialty & Generic

    KERX R&D Expense Quarterly Range, Past 5 Years

    Minimum 1.126M Dec 2008
    Maximum 8.620M Sep 2011
    Average 4.041M